Clive G. Wilson is the J. P. Todd Professor of Pharmaceutics at Strathclyde University, U.K., and the immediate past president of the European Union Federation for Pharmaceutical Sciences. He serves on the steering group of EUFEPS until summer 2012, with a responsibility for linking of the national associations and assisting with science policy and lifelong training of scientists in the pharmaceutical industry.
Major areas of research have been the study of the behaviour of drug formulations in man. With John Hardy in medical physics at Queen’s Medical Centre and later with Professor Davis in pharmacy at Nottingham, he pioneered applications of scintigraphy in the study of physiological and patho-physiological effects of transit on drug absorption following oral, nasal, pulmonary, and ophthalmic delivery. These activities have continued at Glasgow and increased through a network of worldwide collaborations. The focus of the previous work was divided between ocular drug delivery and implant technology and gastrointestinal physiology applied to the study of oral dosage forms. Recently, expansion of the group has accommodated a major programme on the stabilisation of proteins. He has published more than 150 papers, six books, and over 100 reviews and book chapters and has supervised 55 Ph.D. students and an M.D. student. He was made a fellow of the Controlled Release Society in June 2010 and a fellow of the Academy of Pharmaceutical Sciences in September 2010.
CRS Vision Statement
Controlled release sciences are now so commonplace that members of the public hardly notice the applications. We utilise CR products in the home and the workplace, in food, drink, cosmetics, medicines, and incorporated into utility objects. This breadth of application is an immense strength for a professional society drawn from different scientific disciplines. Advance in science is often incremental, with twitches in direction to quickly open new avenues. Examples in my own field would be image-guided medicine, the change in thought provoked in a move from colloid science to nanomedicines, and modulated drug therapies triggered by a biochemical or physical stimulus. We got there by comparing notes, consolidating objectives, and using our talents together.
I have belonged to the controlled release community for more than 40 years. I feel at home in the CRS because I have experienced and drawn from the strengths of the different disciplines that make up the society. In addition, I have been immersed in major initiatives in Europe for the past four years, including the innovative medicines programmes, life-long learning programmes, and the harmonisation of European drug safety legislation. I think that this has helped my continuing education and that I can bring this breadth of vision into the society.
If elected as Secretary, I would continue the focus on cross-disciplinary research and encourage programmes for younger members of the society. Our membership must be given the opportunity to participate, maintaining vitality and reflecting new directions that controlled release sciences will take.